Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2011

01-10-2011

Primary Mediastinal DLBCL: Evolving Biologic Understanding and Therapeutic Strategies

Authors: Pier Luigi Zinzani, Pier Paolo Piccaluga

Published in: Current Oncology Reports | Issue 5/2011

Login to get access

Abstract

Primary mediastinal diffuse large B-cell lymphoma is a quite rare clinicopathologic entity. Molecular analysis shows it to be distinct from other types of diffuse large B-cell lymphoma, and some retrospective analyses suggests that it may respond better to third-generation chemotherapy regimens than to the more commonly used CHOP. The addition of rituximab could reduce these differences; the role of consolidation with local radiotherapy, which is often used to treat residual mediastinal masses, remains. The real role of FDG-PET scanning requires prospective studies, and it is hoped that this may allow the de-escalation of radiation therapy accordingly to yield reliable prognostic information.
Literature
1.
Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980;68(4):509–14.PubMedCrossRef
2.
Levitt LJ, Aisenberg AC, Harris NL, Linggood RM, Poppema S. Primary non-Hodgkin’s lymphoma of the mediastinum. Cancer. 1982;50(11):2486–92.PubMedCrossRef
3.
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.PubMed
4.
Jaffe E, Harris N, Stein H, Vardiman JW. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. In: Kleihues PSLe, editors. World Health Organization classification of tumours. Lyon: lARC; 2001.
5.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haesmatopoietic and lymphoid systems. Lyon: IARC; 2008.
6.
Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol. 1996;20(7):877–88.PubMedCrossRef
7.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89(11):3909–18.
8.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–95.PubMed
9.
Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. WHO Classification of tumors of hematopoietic and lymphoid tissues. Vol 1. Lyon: IARC; 2008. p. 205–1.
10.
Paulli M, Strater J, Gianelli U, et al. Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol. 1999;30(2):178–87.PubMedCrossRef
11.
Barth TF, Leithauser F, Joos S, Bentz M, Moller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3(4):229–34.PubMedCrossRef
12.
Moller P, Lammler B, Eberlein-Gonska M, et al. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch A Pathol Anat Histopathol. 1986;409(1):79–92.PubMedCrossRef
13.
Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162(1):243–53.PubMedCrossRef
14.
Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411–21.PubMedCrossRef
15.
Kanavaros P, Gaulard P, Charlotte F, et al. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas. Am J Pathol. 1995;146(3):735–41.PubMed
16.
Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202(1):60–9.PubMedCrossRef
17.
Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol. 1995;89(4):780–9.PubMedCrossRef
18.
Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112(2):241–7.PubMed
19.
Moller P, Herrmann B, Moldenhauer G, Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer. 1987;40(1):32–9.PubMedCrossRef
20.
Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology. 2004;45(6):619–24.PubMedCrossRef
21.
de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001;25(10):1277–82.PubMedCrossRef
22.
Copie-Bergman C, Gaulard P, Maouche-Chretien L, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94(10):3567–75.PubMed
23.
Alonso MA, Barton DE, Francke U. Assignment of the T-cell differentiation gene MAL to human chromosome 2, region cen––q13. Immunogenetics. 1988;27(2):91–5.PubMedCrossRef
24.
Millan J, Alonso MA. MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Eur J Immunol. 1998;28(11):3675–84.PubMedCrossRef
25.
Alonso MA, Millan J. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J Cell Sci. 2001;114(Pt 22):3957–65.PubMed
26.
Millan J, Montoya MC, Sancho D, Sanchez-Madrid F, Alonso MA. Lipid rafts mediate biosynthetic transport to the T lymphocyte uropod subdomain and are necessary for uropod integrity and function. Blood. 2002;99(3):978–84.PubMedCrossRef
27.
Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15(11):1172–80.PubMedCrossRef
28.
Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31(1):106–12.PubMedCrossRef
29.
Moller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987;69(4):1087–95.PubMed
30.
Leithauser F, Bauerle M, Huynh MQ, Moller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood. 2001;98(9):2762–70.PubMedCrossRef
31.
Hofmann WJ, Momburg F, Moller P. Thymic medullary cells expressing B lymphocyte antigens. Hum Pathol. 1988;19(11):1280–7.PubMedCrossRef
32.
Isaacson PG, Norton AJ, Addis BJ. The human thymus contains a novel population of B lymphocytes. Lancet. 1987;2(8574):1488–91.PubMedCrossRef
33.
Moldenhauer G, Popov SW, Wotschke B, et al. AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies. Blood. 2006;107(6):2470–3.PubMedCrossRef
34.
Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Gene Chromosome Canc. 2001;30(4):393–401.CrossRef
35.
Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87(4):1571–8.PubMed
36.
Wessendorf S, Barth TF, Viardot A, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia. 2007;21(12):2463–9.PubMedCrossRef
37.
Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Gene Chromosome Canc. 2007;46(4):406–15.CrossRef
38.
Weniger MA, Pulford K, Gesk S, et al. Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia. 2006;20(10):1880–2.PubMedCrossRef
39.
Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106(4):1392–9.PubMedCrossRef
40.
Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535–42.PubMedCrossRef
41.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62.PubMedCrossRef
42.
Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104(2):543–9.PubMedCrossRef
43.
Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679–84.PubMedCrossRef
44.
Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2011;116(17):3268–77.CrossRef
45.
Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol. 1996;148(6):2017–25.PubMed
46.
Scarpa A, Moore PS, Rigaud G, et al. Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. Br J Haematol. 1999;107(1):106–13.PubMedCrossRef
47.
Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000;95(2):651–9.PubMed
48.
Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9.PubMedCrossRef
49.
Ritz O, Leithauser F, Hasel C, et al. Downregulation of internal enhancer activity contributes to abnormally low immunoglobulin expression in the MedB-1 mediastinal B-cell lymphoma cell line. J Pathol. 2005;205(3):336–48.PubMedCrossRef
50.
Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15(4):1646–53.PubMed
51.
Zinzani PL, Bendandi M, Frezza G, et al. Primary Mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients. Leuk Lymphoma. 1996;21(3–4):311–6.PubMed
52.
Haioun C, Gaulard P, Roudot-Thoraval F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol. 1989;12(5):425–9.PubMedCrossRef
53.
Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol. 1993;11(12):2306–13.PubMed
54.
Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol. 1999;17(8):2479–85.PubMed
55.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s Disease staging classification. Cancer Res. 1971;31(11):1860–1.PubMed
56.
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987–94.
57.
Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol. 1999;17(3):784–90.PubMed
58.
Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):123–30.PubMedCrossRef
59.
Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90(2):372–6.PubMedCrossRef
60.
Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005;130(5):691–9.PubMedCrossRef
61.
Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258–64.PubMed
62.
Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993;11(7):1336–43.PubMed
63.
Aisenberg AC. Primary large-cell lymphoma of the mediastinum. J Clin Oncol. 1993;11(12):2291–4.PubMed
64.
Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol. 1986;10(3):176–91.PubMedCrossRef
65.
Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999;94(10):3289–93.PubMed
66.
Bertini M, Orsucci L, Vitolo U, et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol. 1991;2(10):733–7.PubMed
67.
Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol. 1990;8(5):804–8.PubMed
68.
Martelli MP, Martelli M, Pescarmona E, et al. MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Ann Oncol. 1998;9(9):1027–9.PubMedCrossRef
69.
Zinzani PL, Martelli M, Bendandi M, et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica. 2001;86(2):187–91.PubMed
70.
Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer. 1988;62(9):1893–8.PubMedCrossRef
71.
Rodriguez J, Pugh WC, Romaguera JE, Cabanillas F. Primary mediastinal large cell lymphoma. Hematol Oncol. 1994;12(4):175–84.PubMedCrossRef
72.
Abrahamsen AF, Lien HH, Aas M, et al. Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study. Ann Oncol. 1994;5(5):433–6.PubMed
73.
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–6.PubMedCrossRef
74.
Guglielmi C, Amadori S, Anselmo AP, et al. Sequential combination chemotherapy of high-grade non-Hodgkin’s lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP). Cancer Invest. 1987;5(3):159–69.PubMedCrossRef
75.
Dunleavy K, Pittaluga SJ, Janik J, et al. Primary mediastinal large B-Cell lymphoma (PMBL) outcome in significantly improved by the addition of Rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. 2005.
76.
Vassilakopoulos T, Angelopoulou M, Galani Z, et al. Excellent outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in primary mediastinal large B-cell lymhoma (PMLBCL). Vol 106: Blood 2005.
77.
• Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9(5):381–385. This study showed no statistically significant differences in terms of CR and PFS rates between MACOP-B and MACOP-B plus rituximab. PubMedCrossRef
78.
• Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22(3):664–670. This study reported CHOP plus rituximab is better than CHOP in terms of CR rate. PubMedCrossRef
79.
Mazzarotto R, Boso C, Vianello F, et al. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys. 2007;68(3):823–9.PubMedCrossRef
80.
Rodriguez J, Conde E, Gutierrez A, et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol. 2008;26(3):171–8.PubMedCrossRef
81.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429–33.PubMed
82.
Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91(5):850–4.PubMed
Metadata
Title
Primary Mediastinal DLBCL: Evolving Biologic Understanding and Therapeutic Strategies
Authors
Pier Luigi Zinzani
Pier Paolo Piccaluga
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 5/2011
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-011-0189-5

Other articles of this Issue 5/2011

Current Oncology Reports 5/2011 Go to the issue

ReviewPaper

Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults

ReviewPaper

Newly Emerging Therapies Targeting Viral-Related Lymphomas

ReviewPaper

Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma

ReviewPaper

Upfront Therapy of Acute Myeloid Leukemia

ReviewPaper

Treatment Strategies in Patients with Core-Binding Factor Acute Myeloid Leukemia

ReviewPaper

Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits